Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

For those who've owned Sigma Healthcare Ltd (ASX: SIG) shares this year, it's been a joyful ride.

Shares in the ASX healthcare stock are up more than 148% this year to date on the back of the planned merger with Chemist Warehouse.

Sigma shares surged nearly 40% shortly after the Australian Competition and Consumer Commission (ACCC) approved the deal.

But with such a rally comes significant profits for those holding large stakes in the company.

According to ASX filings this week, HMC Capital Ltd (ASX: HMC) has completed a large sell-down in its Sigma position.

This raises the question of whether now is a prime opportunity to cash in. Let's take a closer look.

Two lab workers fist pump each other.

Image source: Getty Images

Why is HMC Capital offloading Sigma shares?

The Sigma–Chemist Warehouse deal was approved on 7 November after a lengthy review process that examined potential anti-competition impacts.

Completed via a backdoor listing, the deal saw the pair merge to create a healthcare giant that, according to the ACCC, was "unlikely to substantially lessen competition".

Sigma shares exploded higher on the news. And while plenty of investors were buying for the near-term gains, some shareholders were downsizing their positions.

HMC Capital immediately sold down its stake in Sigma, dropping its holdings from 10.64% to 8.24% on the same day as the ACCC's decision.

The asset manager's reduction in Sigma shares has been ongoing, starting back in April when it sold approximately 4% of its holdings.

HMC initially bought into Sigma at around 70 cents per share in 2022, according to The Australian, making its recent sales an exit at a solid profit.

The financial services company isn't exiting Sigma completely, however. It is just reducing its holdings.

Still, brokers are cautious about what's next. According to CommSec, consensus rates the stock a 'moderate' sell.

This comprises three sell ratings, four holds, and one broker still advising to buy Sigma shares.

Where is HMC Capital now investing?

Where or how HMC will use the funds generated from the sell-downs isn't clear. But elsewhere, the company is channelling its resources into the digital infrastructure space.

In a separate update, the company announced it acquired the iSeek data centre platform in Australia for $400 million. It marks the foundation of its planned DigiCo digital infrastructure platform.

The acquisition, alongside others, could form the basis of a future ASX-listed property trust:

These acquisitions will seed an ASX-listed DigiCo Infrastructure REIT (DigiCo REIT)
2 with [over $4 billion] of [assets under management] AUM…

… Once it is established, it is proposed that DigiCo REIT will be a stapled entity consisting of a company and a registered managed investment scheme. Shares in the company will be stapled to units in the managed investment scheme on a one for one basis to form stapled securities.

Foolish takeaway

Sigma shares are in the limelight after the ACCC approved its merger with Chemist Warehouse this month.

Where to from here is a matter of economic debate, but also the fundamentals of both companies.

Sigma shares are up more than 267% in the past year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »